NASDAQ:AIMTAimmune Therapeutics Stock Price, Forecast & News

Aimmune Therapeutics' stock was trading at $17.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AIMT stock has decreased by 5.5% and is now trading at $16.61. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aimmune Therapeutics.

Aimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aimmune Therapeutics.

Aimmune Therapeutics Inc (NASDAQ:AIMT) released its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.18) by $0.16. The biotechnology company had revenue of $0.58 million for the quarter, compared to analysts' expectations of $1.34 million. The firm's quarterly revenue was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.87) EPS. View Aimmune Therapeutics' earnings history.

11 Wall Street analysts have issued 1 year price targets for Aimmune Therapeutics' stock. Their forecasts range from $15.00 to $66.00. On average, they expect Aimmune Therapeutics' share price to reach $40.09 in the next year. This suggests a possible upside of 141.4% from the stock's current price. View analysts' price targets for Aimmune Therapeutics.

News stories about AIMT stock have trended somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAimmune Therapeutics.

Aimmune Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 17,620,000 shares, an increase of 6.5% from the April 30th total of 16,550,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is presently 11.7 days. Approximately 39.4% of the shares of the stock are short sold. View Aimmune Therapeutics' Current Options Chain.

Some companies that are related to Aimmune Therapeutics include Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Zai Lab (ZLAB), Nektar Therapeutics (NKTR), PPD (SDGR), GW Pharmaceuticals PLC- (GWPH), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Allakos (ALLK), Biohaven Pharmaceutical (BHVN) and Arrowhead Pharmaceuticals (ARWR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Roku (ROKU).

(AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

Aimmune Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (5.90%), BlackRock Inc. (5.57%), State Street Corp (3.37%), Victory Capital Management Inc. (2.89%), Victory Capital Management Inc. (2.89%) and Fiera Capital Corp (2.47%). Company insiders that own Aimmune Therapeutics stock include Andrew Oxtoby, Daniel C Md Adelman, Des Produits Nestle S Societe, Douglas T Sheehy, Eric Bjerkholt, Health Science Us Holdi Nestle, Jayson Donald Alexander Dallas, Patrick G Enright and Stephen George Dilly. View institutional ownership trends for Aimmune Therapeutics.

AIMT stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Wellington Management Group LLP, Bank of New York Mellon Corp, Victory Capital Management Inc., Victory Capital Management Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, and Fiera Capital Corp. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, and Douglas T Sheehy. View insider buying and selling activity for Aimmune Therapeutics.

AIMT stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, Rice Hall James & Associates LLC, Balyasny Asset Management LLC, Burrage Capital Management LLC, and Pictet Asset Management Ltd.. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Andrew Oxtoby, Des Produits Nestle S Societe, Eric Bjerkholt, Health Science Us Holdi Nestle, Jayson Donald Alexander Dallas, and Patrick G Enright. View insider buying and selling activity for Aimmune Therapeutics.

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AIMT stock can currently be purchased for approximately $16.61.

Aimmune Therapeutics has a market capitalization of $1.08 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.

The official website for Aimmune Therapeutics is www.aimmune.com.

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]